Clinical Trial Detail

NCT ID NCT03557970
Title CSF1R Inhibitor JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications

acute myeloid leukemia

Therapies

Edicotinib

Age Groups: adult senior

No variant requirements are available.